NCT01462643已完成2 期
A 22 Day Controlled, Randomized Clinical Study (PPT) Investigating the Anti-psoriatic Efficacy and the Tolerability of an Ointment Containing a Retinoid and a Steroid in Different Concentrations
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Decrease of skin thickness(AUC, area under the curve)
研究概览
简要总结
The aim of the exploratory study is to compare dose related effects of LAS41004 formulations in a non-occlusive PPT.
详细描述
Going for a non-occlusive application design will allow to draw practical conclusions as being similar to a real treatment situation (compared with a occluded design to maximise effects)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 to 75 years of age
- •Caucasian men and women
- •Suffering from mild to moderate plaque psoriasis of at least 6 months duration that is amenable to local therapy
- •With at least one stable psoriatic plaque in an area sufficient for product application meeting the following criteria:
- •located at trunk and/or extremities (plaques located on the head, palms, or sole of feet, intertriginous or genitoanal areas are not suitable)
- •Where more than one plaque is to be used, plaques that are comparable, with at least "2" in each score for scaling, erythema and induration.
- •No more than 3 points difference in total score (sum of scores for scaling, erythema and induration)
- •Negative urine pregnancy test (in female patients of child bearing potential)
- •In the case of women of childbearing potential, using reliable methods of contraception which result in a low failure rate i.e. less than 1% per year (eg contraceptive implants or injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence or vasectomized partner)
排除标准
- •Patients who need systemic treatment for their psoriasis
- •Severe forms of psoriasis or forms of psoriasis other than chronic plaque psoriasis, including:
- •erythroderma
- •exfoliative or
- •pustular psoriasis
- •psoriatic arthritis
- •Changes in the expression of psoriasis within the last 6 weeks prior screening
- •Intensive UV light exposure within two weeks before the beginning of the test as well as during the study and four weeks after the end of the study at the test area
- •Systemic treatment (see table below):
- •Corticosteroids, antibiotics 4 weeks prior to study day 1 and during conduct of study Retinoids Ciclosporin Methotrexate Fumaric acid esters 3 months prior to study day 1 and during conduct of study Anti-inflammatory substances, NSAIDs 2 weeks prior to study day 1 and during conduct of study Biologics 6 months prior to study day 1 and during conduct of study Planned initiation of, or changes to concomitant medication that could affect Psoriasis (e.g. beta blockers, anti-malaria drugs, lithium) 8 weeks before study start and during study
- •Topical treatment of all other body regions with corticosteroids or immunosuppressants where more than 20 % of the body surface area is treated
- •Treatment with any non-marketed drug substance within 4 weeks prior to study day 1
- •Topical treatment of the test area without adequate time for washout
- •Diseases:
- •Skin infections caused by bacteria, viruses or fungi, including but not limited to tuberculosis, syphilis or varicella zoster infection Parasitic infections Rosacea, perioral dermatitis in test area Moderate or severe illness within the last two weeks before first exposure Other known infectious diseases (e.g. hepatitis or AIDS) Other skin diseases that may confound the evaluation of psoriasis
- •Known hypersensitivity to any ingredients of the study drugs,
- •Known calcium metabolism disorders
- •History of malignancy of any organ system
- •Severe impairment of liver or kidney function
- •Pregnancy or lactation
- •Participation in a clinical trial within the last 30 days prior to the start of this study
研究组 & 干预措施
variant1
Experimental
topical ointment, once daily application
干预措施: LAS41004 (Drug)
variant 2
Experimental
topical ointment, once daily application
干预措施: LAS41004 (Drug)
variant 3
Experimental
topical ointment, once daily application
干预措施: LAS41004 (Drug)
variant4
Experimental
topical ointment, once daily application
干预措施: LAS41004 (Drug)
variant 5
Experimental
topical ointment, once daily application
干预措施: LAS41004 (Drug)
variant 6
Placebo Comparator
topical ointment, once daily application
干预措施: LAS41004 (Drug)
control positive
Active Comparator
topical ointment,once daily application
干预措施: LAS41004 (Drug)
结局指标
主要结局
Decrease of skin thickness(AUC, area under the curve)
时间窗: day 1 to day 22
Measurement of skin thickness will be performed by ultrasound (distance between lower border of entry echo and lower border of dermis). The area under the curve, AUC, from day 1 to day 22 will be compared to the reference formulations.
次要结局
- Decrease in scaling(baseline vs day 22)
- decrease in erythema(baseline vs day 22)
- decrease of induration(baseline vs day 22)
- assessment of (s)AE(from baseline to day 22)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Clinical Trial to Investigate Efficacy of LAS41004 in PsoriasisPsoriasisNCT01283698Almirall, S.A.20
已完成
2 期
Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of PsoriasisPsoriasisNCT01119339Almirall, S.A.20
已完成
2 期
Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque TestPsoriasisNCT01360944Almirall, S.A.22
已完成
3 期
Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic KeratosisActinic KeratosisNCT01265602Almirall, S.A.889
已完成
3 期
LAS41008 in Moderate to Severe Chronic Plaque PsoriasisPlaque PsoriasisNCT01726933Almirall, S.A.839